🇺🇸 FDA
Patent

US 9629930

Methods and compositions for treating hemophilia B

granted A61KA61K31/7088A61K45/06

Quick answer

US patent 9629930 (Methods and compositions for treating hemophilia B) held by Sangamo Biosciences, Inc. expires Mon Apr 20 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Sangamo Biosciences, Inc.
Grant date
Tue Apr 25 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 20 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61K, A61K31/7088, A61K45/06, A61K48/005, A61P